What is the confirmed market size and growth trajectory for the global bioreactors market?
The market was valued at USD 15.2 billion in 2025 and is projected to grow at a CAGR of 12.5% to USD 43.87 billion by 2035. Single-use bioreactors are the fastest-growing type. Mammalian cell culture is the dominant application. Pharmaceutical and biopharma manufacturers are the largest end-user. CDMOs are the fastest-growing end-user. North America leads; Asia-Pacific is the fastest-growing region. Upstream bioprocessing is the largest workflow segment.

How do biologics drive structural bioreactor market demand above conventional pharmaceutical manufacturing?
Biologic drugs — protein-based therapeutics including mAbs, recombinant proteins, vaccines, and cell and gene therapies — require bioreactor-based cell culture production that has no equivalent in conventional small-molecule pharmaceutical manufacturing. Each approved biologic creates a permanent installed base of bioreactor capacity at the production facility — growing with the drug’s commercial volume — and each new biologic in clinical development creates process development and clinical manufacturing bioreactor demand years before commercial production begins. The biologics pipeline’s growing share of pharmaceutical approvals creates compounding bioreactor demand from both commercial scale-up and development-stage manufacturing simultaneously.

What is Thermo Fisher Scientific’s bioreactor portfolio and how does its scale address the market?
Thermo Fisher Scientific’s bioreactor portfolio spans single-use HyPerforma S.U.B. systems from 2L to 5,000L scale, the DynaDrive single-use bioreactor family for bench-scale through commercial manufacturing, and reusable controlled process vessels — serving biopharma, CDMO, and academic customers across the full bioproduction workflow from process development to commercial scale. Thermo Fisher’s position as the world leader in serving science with USD 44.56 billion in 2025 revenue provides the R&D investment, commercial reach, and manufacturing scale that positions its bioreactor portfolio as a primary platform choice for global biopharma manufacturers.

How do CDMOs create the fastest-growing bioreactor procurement category?
Contract development and manufacturing organisations — who manufacture biologic drugs on behalf of biopharma clients who outsource production rather than building owned facilities — are the fastest-growing bioreactor procurement category because each CDMO capacity expansion investment in bioreactor systems serves multiple client drug programmes simultaneously. CDMO bioreactor procurement scales with the outsourced biologics manufacturing market, which is growing faster than captive biopharmaceutical manufacturing as development-stage biotechs and virtual biopharma companies — without manufacturing assets — rely entirely on CDMOs for clinical and commercial production.

What makes cell and gene therapy bioreactor production the highest-complexity and fastest-growing application?
Cell and gene therapy production — using bioreactors for viral vector (AAV, lentivirus, adenovirus) expansion, CAR-T cell activation and expansion, and plasmid DNA production — requires bioprocessing conditions fundamentally different from conventional CHO mAb production. Viral vector bioreactors must achieve high transduction efficiency at small batch sizes (often 50L to 500L) with stringent containment requirements above standard mammalian cell culture, while cell therapy bioreactors must maintain T-cell viability and potency across closed-system workflows. Each new cell and gene therapy approval creates unique bioreactor configuration requirements that sustain equipment innovation investment.

How does the transition from stainless steel to single-use bioreactors create commercial inflection in the market?
The transition from conventional stainless steel bioreactors — requiring cleaning validation, steam sterilisation, and weeks of turnaround time between batches — to single-use polymer film bioreactor bags that are disposed after each batch eliminates cleaning validation costs, reduces cross-contamination risk between products, and cuts batch changeover time from weeks to days. For multi-product CDMO facilities producing dozens of different client drug programmes, single-use bioreactors enable the operational flexibility that stainless steel infrastructure cannot provide — sustaining the single-use transition at CAGR above the overall bioreactors market.